Prospective Study Into The Necessity Of Hemogram On Day 8 In Oral Vinorelbine And Cisplatin Regimen.

e18011 Background: One of the standard treatments for metastatic non-small-cell lung cancer patients is the combination of cisplatin plus vinorelbine. This regimen is associated with a high rate of severe neutropenia, and a hemogram is therefore routinely performed on day 8 before the administration of vinorelbine. However, no prospective study has ever examined the rate of neutropenia detected in this hemogram or the rate of discontinuation of chemotherapy as a result. Since one of the objectives in the treatment of advanced lung cancer is to maintain quality of life, we performed this prospective study of cisplatin plus vinorelbine to address the question of whether this hemogram on day 8 could be avoided, thus eliminating unnecessary venipunctures without endangering patient safety. Methods: We included 58 chemotherapy-naïve advanced NSCLC patients from 10 centers. They received intravenous doses of cisplatin on day 1 plus oral vinorelbine on days 1 and 8, every 3 weeks, for a maximum of six cycles. Median age was 61 years; 87% were males; ECOG 1: 66%. Results: Of 189 cycles analyzed, vinorelbine was administered on day 8 in 661 (97.8%), and the dose was reduced or canceled in 15 (2.2%; IC 95%: 0.5 - 5.45) due to hematological toxicity. Conclusions: The hemogram on day 8 could potentially be avoided in patients ECOG 0-1 while still maintaining an acceptable safety margin.